Dr. Susana Banerjee spoke to ecancer about the findings of the SOLO1 trial presented at the ESMO 2020 Virtual Congress.
She first talked about the rationale behind using a PARP inhibitor (olaparib), for maintenance treatment of patients with newly diagnosed ovarian cancer and BRCA mutation.
Dr Banerjee then went on to explain how the results of the treatment group were better than the placebo group and how the findings of this study can impact the current ovarian cancer treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.